Article Data

  • Views 1656
  • Dowloads 193

Original Research

Open Access

Prognostic value of Ki-67 in patients with ovarian cancer

  • Su Wan1,2
  • Chang Su1
  • Yong Wang3
  • Jin Ding1
  • Qingya Jiang1
  • Huafeng Ding1,*,
  • Guantai Ni1,*,

1Department of Obstetrics and Gynecology, The First Affiliated Hospital of Wannan Medical College, 241000 Wuhu, Anhui, China

2Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Soochow University, 215000 Suzhou, Jiangsu, China

3Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wannan Medical College, 241000 Wuhu, Anhui, China

DOI: 10.22514/ejgo.2023.051

Submitted: 12 March 2023 Accepted: 05 May 2023

Online publish date: 24 July 2023

*Corresponding Author(s): Huafeng Ding E-mail: dinghuafeng@wnmc.edu.cn
*Corresponding Author(s): Guantai Ni E-mail: niguantai@yjsyy.com

Abstract

This study aimed to investigate the prognostic value of Ki-67 antigen (Ki-67) in patients with epithelial ovarian cancer. A retrospective review identified a cohort of 78 patients with epithelial ovarian cancer. The association between Ki-67 expression and clinicopathological characteristics and survival was analyzed. High Ki-67 expression was significantly associated with high stage, high histological grade, ascites, and high level of cancer antigen 125 (CA125) (p = 0.011, p = 0.031, p = 0.033, p = 0.004, respectively). In addition, high Ki-67 expression was significantly associated with poor prognosis (p = 0.002), which was further confirmed using a multivariate Cox regression hazards model (Hazard Ratio (HR) = 1.797, 95% confidence interval (CI) = 1.038–3.111, p = 0.026). In conclusion, Ki-67 expression may be a significant prognostic factor in epithelial ovarian cancer.

Keywords

Ki-67; Ovarian cancer; Survival; Prognosis


Cite and Share

Su Wan,Chang Su,Yong Wang,Jin Ding,Qingya Jiang,Huafeng Ding,Guantai Ni. Prognostic value of Ki-67 in patients with ovarian cancer. European Journal of Gynaecological Oncology. 2024.doi:10.22514/ejgo.2023.051.

References

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[2] Wichmann IA, Cuello MA. Obesity and gynecological cancers: a toxic relationship. International Journal of Gynecology & Obstetrics. 2021; 155: 123–134.

[3] Havasi A, Cainap SS, Havasi AT, Cainap C. Ovarian cancer-insights into platinum resistance and overcoming it. Medicina. 2023; 59: 544.

[4] Ciucci A, Buttarelli M, Fagotti A, Scambia G, Gallo D. Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application. Cellular and Molecular Life Sciences. 2022; 79: 364.

[5] McGee J, Bookman M, Harter P, Marth C, McNeish I, Moore KN, et al. Fifth ovarian cancer consensus conference: individualized therapy and patient factors. Annals of Oncology. 2017; 28: 702–710.

[6] El Bairi K, Al Jarroudi O, Afqir S. Inexpensive systemic inflammatory biomarkers in ovarian cancer: an umbrella systematic review of 17 prognostic meta-analyses. Frontiers in Oncology. 2021; 11: 694821.

[7] Pei R, Zhang L, Xie C, Lu Z, Wang G, Yang Z. Prognostic value of Ki-67 expression in patients with extensive-stage small cell lung cancer. Future Oncology. 2017; 13: 1247–1252.

[8] Menon SS, Guruvayoorappan C, Sakthivel KM, Rasmi RR. Ki-67 protein as a tumour proliferation marker. Clinica Chimica Acta. 2019; 491: 39–45.

[9] Finkelman BS, Zhang H, Hicks DG, Turner BM. The Evolution of Ki-67 and breast carcinoma: past observations, present directions, and future considerations. Cancers. 2023; 15: 808.

[10] Sallum LF, Andrade L, Bastos Eloy da Costa L, Ramalho S, Ferracini AC, Natal RA, et al. BRCA1, Ki67, and β-catenin immunoexpression is not related to differentiation, platinum response, or prognosis in women with low-and high-grade serous ovarian carcinoma. International Journal of Gynecological Cancer. 2018; 28: 437–447.

[11] Mahadevappa A, Krishna SM, Vimala MG. Diagnostic and prognostic significance of Ki-67 immunohistochemical expression in surface epithelial ovarian carcinoma. Journal of Clinical and Diagnostic Research. 2017; 11: EC08–EC12.

[12] Tuninetti V, Ghisoni E, Pignata S, Picardo E, Raspagliesi F, Andreetta C, et al. Ki67 as a predictor of response to PARP inhibitors in platinum sensitive BRCA wild type ovarian cancer: the MITO 37 retrospective study. Cancers. 2023; 15: 1032.

[13] Finkelman BS, Zhang H, Hicks DG, Turner BM. The Evolution of Ki-67 and breast carcinoma: past observations, present directions, and future considerations. Cancers. 2023; 15: 808.

[14] Qiu D, Cai W, Zhang Z, Li H, Zhou D. High Ki-67 expression is significantly associated with poor prognosis of ovarian cancer patients: evidence from a meta-analysis. Archives of Gynecology and Obstetrics. 2019; 299: 1415–1427.

[15] Rödel F, Zhou S, Győrffy B, Raab M, Sanhaji M, Mandal R, et al. The prognostic relevance of the proliferation markers Ki-67 and Plk1 in early-stage ovarian cancer patients with serous, low-grade carcinoma based on mRNA and protein expression. Frontiers in Oncology. 2020; 10: 558932.

[16] Grabowski JP, Martinez Vila C, Richter R, Taube E, Plett H, Braicu E, et al. Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer. International Journal of Gynecologic Cancer. 2020; 30: 498–503.

[17] Hu J, Jiao X, Zhu L, Guo H, Wu Y. Establishment and verification of the nomogram that predicts the 3-year recurrence risk of epithelial ovarian carcinoma. BMC Cancer. 2020; 20: 938.

[18] Kaya R, Takanashi H, Nakajima A, Saito R, Yamaguchi N, Morimoto K, et al. Prognostic significance of Ki67 during neoadjuvant chemotherapy in primary unresectable ovarian cancer. Journal of Obstetrics and Gynaecology Research. 2021; 47: 3979–3989.

[19] Sehouli J, Braicu EI, Richter R, Denkert C, Jank P, Jurmeister PS, et al. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the tumor bank ovarian cancer network. Human Pathology. 2019; 85: 299–308.

[20] Grabowski JP, Martinez Vila C, Richter R, Taube E, Plett H, Braicu E, et al. Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer. International Journal of Gynecologic Cancer. 2020; 30: 498–503.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top